All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Recombinant Erwinia asparaginase: Key clinical considerations in pediatric and young adults with ALL
The ALL Hub was pleased to speak with Luke Maese, pediatric hematologist oncologist at the University of Utah Huntsman Cancer Institute and Primary Children's Hospital, Salt Lake City, US. We asked, What are the clinical considerations for the use of recombinant Erwinia asparaginase in pediatric and young adult patients with acute lymphoblastic leukemia (ALL)?
This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Agree
100%
Disagree
0%
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox